The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

Find Therapeutics has dosed the first subject in a Phase I trial of FTX-101 as a potential treatment for chronic optic ...